Search
Press release
Health Care
September 3, 2019

Evonik acquires a surface modification technology platform from Interface Biologics to further expand its medical device capabilities

  • Endexo® platform enhances medical device biocompatibility
    by reducing the risks of thrombosis, infections and biofouling
  • Multiple device companies have licensed the clinically proven technology for cardiovascular and neurovascular products
  • Acquisition further strengthens Evonik’s medical device portfolio of biomaterials and application technology services

Evonik, a global leader in biomaterials for use in medical implant applications, today announced the acquisition of the Endexo® surface modification business of Interface Biologics, a privately-held material science company located in Toronto, Canada. The acquisition is an important next step to further strengthen the capabilities of the growth engine Health & Care.

Endexo® is a proprietary additive technology that enhances the biocompatibility of medical devices that come into contact with blood, tissue or other biological fluids. The low molecular weight fluoro-oligomers used in Endexo® are incorporated during the device manufacturing process and migrate to within nanometres of the surface. By suppressing procoagulant protein conformation, decreasing platelet adhesion and inhibiting platelet activation, Endexo® reduces the risk of thrombotic events. It also suppresses bacteria adhesion and biofilm formation to reduce infection risk.

A number of medical device companies have licensed the use of the Endexo® technology in cardiovascular and other applications. Some of these products are already commercially available, while others are part of promising clinical trials.

“We are excited to onboard the Endexo® technology in our portfolio.” said Jean-Luc Herbeaux, SVP and General Manager of the Health Care business line of Evonik. “Endexo® expands our ability to serve as a development partner and solution provider to medical device companies worldwide. The team of Interface Biologics has done an exemplary job developing this innovative technology and bringing it to market. We look forward to applying our global business development capabilities and technical prowess to further expand the geographic and application footprint of Endexo®.”

“We have been working closely with Evonik on joint development opportunities over the last few years,” said Tom Reeves, President and CEO of Interface Biologics. “I am confident that the combination of the Endexo® technology platform and the technical, commercial and financial resources of Evonik will enable the rapid acceleration of the business across broad sectors of the medical device market.”

Additional terms of the agreement will not be disclosed.

Company information

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-oriented innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world. In fiscal 2018, the enterprise with more than 32,000 employees generated sales of €13.3 billion and an operating profit (adjusted EBITDA) of €2.15 billion from continuing operations.

About Nutrition & Care

The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,200 employees, and generated sales of around
€4.6 billion in 2018.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.